List of Press Releases
Ash Access Technology, Inc. Has Been Granted A Key United States Patent For Its Novel Antimicrobial / Antithrombotic Catheter Lock and Catheter Flush Technologies
AUGUST 27, 2010 EST (Lafayette, Indiana) - - - Ash Access Technology, Inc. (AAT) today announced that a key US patent protecting its proprietary catheter lock solution intellectual property (IP) has been issued by the United States Patent and Trademark Office. The Company now has multiple patents covering its core technology issued in the United States, 23 European countries and Mexico, and patents pending in 15 additional countries.
“We are very pleased to have been granted this patent by the US Patent Office,“ said Robert B. Truitt, President and CEO of Ash Access Technology. “It represents the final milestone in securing protection of this intellectual property in all major markets throughout the world. Not only does this validate the uniqueness of our lead product Zuragen™ in the marketplace as a breakthrough antimicrobial catheter lock solution, but the patent also protects a larger body of core infection prevention formulations that are at the root of a diverse anti-infective pipeline.”
Zuragen™ is an antimicrobial and antithrombotic catheter solution designed to reduce catheter-related infection events in hemodialysis catheters and safely maintain catheter patency and function. It was recently studied in the pivotal AZEPTIC™ trial in 415 hemodialysis patients and demonstrated a significant reduction in catheter-related bloodstream infections and bacteremia events, superior patency results and an attractive safety profile compared to the current standard of care---high concentration Heparin. AAT is seeking FDA approval to commercialize Zuragen™. The AZEPTIC™ clinical trial was partially funded by the Indiana 21st Century Fund and National Institutes of Health.
About Ash Access Technlogy, Inc.
Ash Access Technology, Inc. is a privately held specialty pharmaceutical / medical device company focused on the development and commercialization of proprietary products and devices to improve vascular access and infection control outcomes. The Company's diverse product portfolio includes an innovative hemodialysis catheter, CentrosTM, and unique antimicrobial therapeutics being developed for the prevention of infections in numerous healthcare settings. Ash Access Technology is located in Lafayette, Indiana in the INOK Business Center.
The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as other risk factors may affect the actual results achieved by the Company.